SPL UNCLASSIFIED SECTION
Homeopathic Digestive Aid Medicine
20 CAPSULES
Homeopathic Digestive Aid Medicine
20 CAPSULES
For temporary relief of digestive symptoms such as fullness, pressure or "gas" that occur after eating.
1 capsule contains 330 mg Penicillium roquefortii 4X in a base of lactose.
Lactose, Capsule shells consist of Hypromellose (HPMC).
Do not use this product if imprinted inner blister pack is broken or if imprinted security strip on carton is torn.
1–3 capsules daily, either before breakfast or at bedtime.
If symptoms persist more than a few days, contact a licensed practitioner. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health care professional before taking this product.
Keep this and all medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.
Protect from light and heat.
Made in Germany
Distributed by:
SANUM USA Corp.
1465 Slater Road
Ferndale, WA 98248
Manufactured By:
Sanum-Kehlbeck
GmbH & Co. KG
Rev. 05/2008
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60681-1103-1 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-de8a-621f-e053-dbdaa90a74ad | Pleo™ Fort CAPSULES 4X |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60681-1103-1 | Pleo Fort | 20 in 1 BLISTER PACK | CAPSULE | 20 | 1 | |
| 60681-1103-1 | Pleo Fort | 1 in 1 CARTON | CAPSULE | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60681-1103 | PLEO FORT (PENICILLIUM ROQUEFORTI) CAPSULE [SANUM KEHLBECK GMBH & CO. KG] | 1 | Legacy NDC, 2 package rows | 20110113_29e32853-0188-4f4b-989d-e80e70c8efbe.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| penicillium roqueforti | ACTIVE INGREDIENT | 7ORP6R724L | 1 | |
| penicillium roqueforti | ACTIVE MOIETY | 7ORP6R724L | 1 | |
| hypromellose | INACTIVE INGREDIENT | 3NXW29V3WO | 1 | |
| lactose | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60681-1103 | 60681-1103-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| penicillium roqueforti | 7ORP6R724L | ACTIB |
| lactose | J2B2A4N98G | IACT |
| hypromellose | 3NXW29V3WO | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, CHEWABLE / ORAL | 11.8 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GEL / RECTAL | 348 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, ORALLY DISINTEGRATING / ORAL | 41 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, DELAYED RELEASE / ORAL | 105 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GRANULE / ORAL | 45 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| lactose | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED PELLETS / ORAL | 3.32 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | JELLY / TOPICAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 221 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CREAM / TOPICAL | 0.1 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, DELAYED RELEASE / ORAL | 79 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / OPHTHALMIC | 0.5 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | INSERT / VAGINAL | 54.21 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GRANULE, FOR SUSPENSION / ORAL | 1.7 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, EXTENDED RELEASE / ORAL | 119.7 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SYRUP / ORAL | 250 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE / ORAL | 1488 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / ORAL | 305 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SYSTEM / TOPICAL | 54 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | LOTION / TOPICAL | 0.1 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, EXTENDED RELEASE / ORAL | 1472 mg | ||
| lactose | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SHAMPOO / TOPICAL | 3 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f0dbce71-9e88-4c14-b19e-0af1b7c82556 | 29e32853-0188-4f4b-989d-e80e70c8efbe | 2009-10-09 | Warnings | f0dbce71-9e88-4c14-b19e-0af1b7c82556 29e32853-0188-4f4b-989d-e80e70c8efbe |
Adverse event summaries are temporarily unavailable. Other product information remains available.